A prospective clinical observational study based on an independent CRC cohort from our medical center was carried out to confirm that PLCG2 was a risk factor for the outcome of CRC patients and was closely related to clinicopathological features (Clinical Trial Registry No. NCT04714814). This evidence concerns the gene PLCG2 and colorectal carcinoma.